Home | miyaokalab

Genome Editing in Human iPS Cells to Study and Cure Disease

Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More

English

日本語

News

2025. 3. 2.　Lab ski & snowboard trip to Madarao

2025. 3. 1.　Daisuke Matsumoto comments in Springer Nature Japan Research Advisory Forum 2024 (in Japanese).

2024. 12. 27.　Kayoko Shinozaki and Yuga Yasuda sre awarded the Belle Foundation Fellowship!!

2024. 11. 1.　Noa Tozawa joins the lab as an Intern!

2024. 10. 4.　Lab trip to the Nakatsugawa trout fishing ground.

2024. 10. 1.　Hiroto Serita and Ryo Shiraki join the lab as Interns!

2024. 9. 19.　Isolation and analysis of >1,000 genome-edited iPS cell clones in collaboration with Yamaha Mortor is out in bioRxiv.

2024. 9. 2.　Daisuke Matsumoto joins the lab as a Staff Scientist!

2024. 8. 19.　Tomoya Okada joins the lab as a Summer Intern!

2024. 5. 13.　Our paper on effects of fusion of Cas9 and histone variants to inhibit NHEJ is out in PLOS ONE.

2024. 4. 1.　Kai Zhang joins the lab as a graduate student!

2024. 3. 29.　A staff scientist position is still open.

2024. 3. 26.　Miyaoka is awarded the Excellent Presentation Award at the Congress of the Japanese Society for Regenerative Medicine.

2024. 3. 17.　Lab ski trip to Togari Onsen

2024. 3. 11.　Lanyu Huang and Minato Maeda win the best presentation award in the Institutional poster presentation competition.